Start-up of new clinical trials put on hold at Sachsska barnsjukhuset
Calmark Sweden AB (publ) announces today that new clinical trials in cooperation with the research unit at the children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm, will not be able to start in the coming months. The reason is that resources must be re-prioritized due to the situation with COVID-19. Further notice is expected.
“The current situation is unfortunate, but we fully understand the priorities set by the healthcare system,” says Anna Söderlund, CEO. “Our current focus is on the production and marketing of our two CE-marked products, Neo-Bilirubin and COVID19-LDH.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.